References
- Stasi R, Bosworth J, Rhodes E, Shannon MS, Willis F, Gordon-Smith EC. Thrombopoietic agents. Blood Rev. 2010;24(4–5):179–90.
- Ruiz-Argüelles A. Anemias hemolíticas inmunológicas. In: , Ruiz-Argüelles GJ(eds.) Fundamentos de Hematologìa. 4th ed. Editorial Médica Panamericana. Mexico City, México; 2009. p. 107–16.
- Norton A, Roberts I. Management of Evans syndrome. Br J Haematol. 2006;132(2):125–37.
- González-Nieto JA, Martin-Suarez I, Quattrino S, Ortiz-Lopez E, Muñoz-Beamud FR, Colchero-Fernández J, et al. The efficacy of romiplostim in the treatment of severe thrombocytopenia associated to Evans syndrome refractory to rituximab. Lupus. 2011;20(12):1321–3.
- Rodríguez-Mejorada S, Rosel-Gómez C, Rosado-Castro RA, Domingo-Padilla MA, Ruiz-Delgado GJ. Romiplostim reverts the thrombocytopenia in dengue hemorrhagic fever. Hematol Oncol Stem Cell Ther. 2011;4:48–9.
- Ruiz-Delgado GJ, Lutz-Presno J, Ruiz-Argüelles GJ. Romiplostin may revert the thrombocytopenia in graft versus host disease. Hematology. 2011;16:108–9.
- Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL, et al. Phase II study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood. 2010;116:3163–70.
- Moussa MM, Mowafy N. Pre-operative use of romiplostim in thrombocytopenic patients with chronic hepatitis C and liver cirrhosis. J Gastroenterol Hepatol. 2012 July 31. doi: 10.1111/j.1440-1746.2012.07246.x. [Epub ahead of print].
- D'Arena G, Cascavilla N. Romiplostim for chronic lymphocytic leukemia-associated immune thrombocytopenia. Leuk Lymphoma. 2011;52:701–4.
- Demeter J, Istenes I, Fodor A, Paksi M, Dombi P, Valasinyószki E, et al. Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. Pathol Oncol Res. 2011;17:141–3.
- Newland A. Thrombopoietin: too much or too little? Hematology. 2012;17( Suppl. 1):S-166–8.
- No authors listed. Eltrombopag. Idiopathic thrombocytopenic purpura after treatment failure: romiplostim is a better option. Prescrire Int. 2010;19(105):15.
- Mitsuhashi K, Ishiyama M, Imai Y, Shiseki M, Mori N, Teramura M, et al. Combined romiplostin and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy. Brit J Haematol. 2012;158:798–800.